A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.
Epistemonikos ID: 832117c7ecc178b28b50f40fbd2dbf4d562d71df
First added on: Sep 29, 2026